Testing Inavolisib in early-stage breast cancer with PIK3CA mutation
Treatments studied
Part of Cancer, Skin clinical trials.
This trial is testing a drug called Inavolisib (a type of targeted therapy) given before surgery for people with early-stage, hormone receptor-positive, HER2-negative breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding Inavolisib to standard endocrine therapy can shrink the tumor more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II or III breast cancer that is hormone receptor-positive (ER-positive) and HER2-negative.
- You are a candidate for hormone therapy and are planning to have surgery after treatment.
- Your tumor has a PIK3CA mutation (a specific gene change).
- Your tumor's Ki-67 score (a measure of how fast cells are growing) is at least 5%.
- You do not have metastatic (stage IV), inflammatory, or bilateral breast cancer.
- You have not had prior treatment for this breast cancer (like surgery, radiation, or chemotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new targeted pill (inavolisib) plus hormone therapy (fulvestrant) can slow or stop breast cancer growth in people whose cancer has a specific genetic change called a PIK3CA mutation. It is for patients whose disease worsened after previous hormone-and-CDK-inhibitor treatment.
This trial tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) compared to a placebo plus two of the drugs (ribociclib and fulvestrant) for people with advanced hormone receptor-positive breast cancer who have not had prior treatment for advanced disease. The goal is to see if adding inavolisib improves outcomes.
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
This trial tests a combination of medications (inavolisib, pertuzumab, trastuzumab, and nab-paclitaxel) given before surgery to shrink tumors in people with HER2-positive early breast cancer that also has a specific gene change (PIK3CA mutation). The goal is to see if this treatment is effective and safe.
This study observes how inavolisib (a new cancer drug) works in patients with a specific type of advanced breast cancer in everyday clinical practice. Researchers will track your medical records, imaging, and lab results over time to understand how well the treatment works and its safety profile.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.